Qihan Biotech develops multiplexable gene editing technologies to create immunologically privileged allogenic cells and xenogeneic organs for transplantation. This approach addresses the critical shortage of compatible organ donors and the challenges of organ rejection in transplant patients.
Funding
$16M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
ZCFounders
Product
Problem
The demand for organ and cell transplantation is significantly higher than the available supply of compatible donors. Allogeneic transplants often face the challenge of immune rejection, requiring patients to undergo immunosuppressive therapies with associated risks.
Solution
Qihan Biotech is developing multiplexable gene editing technologies to engineer allogeneic cells and xenogeneic organs that are immunologically privileged, aiming to overcome the limitations of donor shortages and immune rejection in transplantation. By precisely modifying multiple genes, they create cells and organs that are less likely to be recognized and rejected by the recipient's immune system. This approach seeks to expand the pool of potential donors and reduce the need for immunosuppression, ultimately improving transplant outcomes and accessibility.
Target Audience
The primary target audience includes patients in need of organ or cell transplantation, transplant centers, and researchers in the fields of transplantation immunology and regenerative medicine.
Features
- Multiplexable gene editing platform for precise modification of multiple genes simultaneously.
- Genome editing to create immune-privileged cells and organs.
- Focus on allogeneic cells and xenogeneic organs for transplantation.